Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Cash & Equivalents (2016 - 2025)

Capricor Therapeutics has reported Cash & Equivalents over the past 15 years, most recently at $287.8 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $287.8 million for Q4 2025, up 2450.26% from a year ago — trailing twelve months through Dec 2025 was $287.8 million (up 2450.26% YoY), and the annual figure for FY2025 was $287.8 million, up 2450.26%.
  • Cash & Equivalents for Q4 2025 was $287.8 million at Capricor Therapeutics, up from $19.5 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for CAPR hit a ceiling of $287.8 million in Q4 2025 and a floor of $6.2 million in Q1 2024.
  • Median Cash & Equivalents over the past 5 years was $18.0 million (2022), compared with a mean of $37.4 million.
  • Biggest five-year swings in Cash & Equivalents: plummeted 81.81% in 2023 and later soared 2450.26% in 2025.
  • Capricor Therapeutics' Cash & Equivalents stood at $34.9 million in 2021, then plummeted by 72.47% to $9.6 million in 2022, then surged by 53.02% to $14.7 million in 2023, then dropped by 23.19% to $11.3 million in 2024, then soared by 2450.26% to $287.8 million in 2025.
  • The last three reported values for Cash & Equivalents were $287.8 million (Q4 2025), $19.5 million (Q3 2025), and $23.2 million (Q2 2025) per Business Quant data.